{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:18:46Z","timestamp":1772119126749,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Heart Foundation of Northern Sweden","award":["-"],"award-info":[{"award-number":["-"]}]},{"name":"The 1,6 Million Club","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To develop a model for systematic introduction and to test the feasibility in a chronic disease population. We also investigated how the approach was received by the patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The systematic introduction approach is a seven-step procedure: step 1, define a few main criteria; step 2, primary scan patients with the one or two main criteria using computerized medical records\/databases\/clinical registries; step 3, identify patients applying the other predefined criteria; step 4, evaluate if any examinations\/laboratory test updates are required; step 5, summon identified patients to the clinic with an information letter; step 6, discuss treatment with the patient and prescribe if appropriate; and step 7, follow up on initiated therapy and evaluate the applied process. The model was tested in a case study during introduction of the new drug sacubitril-valsartan in a heart failure population. In total, 76 out of 1924 patients were identified to be eligible for sacubitril-valsartan and summoned to the clinic to discuss treatment. Patient experiences with the approach were investigated in an interview study with general inductive approach using qualitative content analysis. This resulted in three final categories: a good approach, role of the information letter, and trust in care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The systematic introduction approach ensures that strict criteria are used in the selection process and that a treatment can be implemented in eligible patients within a specified population with limited resources and time. The model was effective in our case study and maintained the patient\u2019s confidence in healthcare.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-020-02979-w","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T20:02:37Z","timestamp":1597953757000},"page":"125-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study"],"prefix":"10.1007","volume":"77","author":[{"given":"Helena","family":"Norberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellinor","family":"Bergdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin Hellstr\u00f6m","family":"\u00c4ngerud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-7791","authenticated-orcid":false,"given":"Krister","family":"Lindmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"2979_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010716-104952","volume":"57","author":"KL Lavoie","year":"2017","unstructured":"Lavoie KL, Rash JA, Campbell TS (2017) Changing provider behavior in the context of chronic disease management: focus on clinical inertia. Annu Rev Pharmacol Toxicol 57:263\u2013283. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010716-104952","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2979_CR2","doi-asserted-by":"publisher","first-page":"e004302","DOI":"10.1161\/circheartfailure.117.004302","volume":"11","author":"LR Sangaralingham","year":"2018","unstructured":"Sangaralingham LR, Sangaralingham SJ, Shah ND, Yao X, Dunlay SM (2018) Adoption of sacubitril\/valsartan for the management of patients with heart failure. Circ Heart Fail 11:e004302. https:\/\/doi.org\/10.1161\/circheartfailure.117.004302","journal-title":"Circ Heart Fail"},{"key":"2979_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","volume":"5","author":"N Luo","year":"2017","unstructured":"Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, Greiner MA, Hammill BG, Hardy NC, Turner SJ, Laskey WK, Curtis LH, Hernandez AF, Mentz RJ, O\u2019Brien EC (2017) Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from get with the Guidelines-Heart Failure (GWTG-HF). JACC Heart Fail 5:305\u2013309. https:\/\/doi.org\/10.1016\/j.jchf.2016.12.018","journal-title":"JACC Heart Fail"},{"key":"2979_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.clpt.6100249","volume":"82","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S (2007) Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 82:143\u2013156. https:\/\/doi.org\/10.1038\/sj.clpt.6100249","journal-title":"Clin Pharmacol Ther"},{"key":"2979_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ageing\/afw119","volume":"45","author":"A Nakano","year":"2016","unstructured":"Nakano A, Egstrup K, Svendsen ML, Schj\u00f8dt I, Jakobsen L, Mehnert F, Johnsen SP (2016) Age- and sex-related differences in use of guideline-recommended care and mortality among patients with incident heart failure in Denmark. Age Ageing 45:635\u2013642. https:\/\/doi.org\/10.1093\/ageing\/afw119","journal-title":"Age Ageing"},{"key":"2979_CR6","doi-asserted-by":"publisher","first-page":"e12459","DOI":"10.1111\/1755-5922.12459","volume":"36","author":"A Jonsson","year":"2018","unstructured":"Jonsson A, Norberg H, Bergdahl E, Lindmark K (2018) Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population. Cardiovasc Ther 36:e12459. https:\/\/doi.org\/10.1111\/1755-5922.12459","journal-title":"Cardiovasc Ther"},{"key":"2979_CR7","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","volume":"20","author":"G Savarese","year":"2018","unstructured":"Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstr\u00f6m U, Lund LH (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20:1326\u20131334. https:\/\/doi.org\/10.1002\/ejhf.1182","journal-title":"Eur J Heart Fail"},{"key":"2979_CR8","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129\u20132200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"2979_CR9","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/cir.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld JA, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136:e137\u2013e161. https:\/\/doi.org\/10.1161\/cir.0000000000000509","journal-title":"Circulation"},{"key":"2979_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"2979_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.nedt.2003.10.001","volume":"24","author":"UH Graneheim","year":"2004","unstructured":"Graneheim UH, Lundman B (2004) Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 24:105\u2013112. https:\/\/doi.org\/10.1016\/j.nedt.2003.10.001","journal-title":"Nurse Educ Today"},{"key":"2979_CR12","unstructured":"National Board of Health and Welfare. Drug statistics [internet]. 2016 Stockholm. [cited 3 Aug 2020]; Available from: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/statistik\/statistikamnen\/lakemedel\/."},{"key":"2979_CR13","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1136\/hrt.2006.099523","volume":"94","author":"MJ Lenzen","year":"2008","unstructured":"Lenzen MJ, Rosengren A, Scholte OP, Reimer WJ et al (2008) Management of patients with heart failure in clinical practice: differences between men and women. Heart 94:e10. https:\/\/doi.org\/10.1136\/hrt.2006.099523","journal-title":"Heart"},{"key":"2979_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijcard.2017.01.018","volume":"232","author":"C Vitale","year":"2017","unstructured":"Vitale C, Fini M, Spoletini I, Lainscak M, Seferovic P, Rosano GM (2017) Under-representation of elderly and women in clinical trials. Int J Cardiol 232:216\u2013221. https:\/\/doi.org\/10.1016\/j.ijcard.2017.01.018","journal-title":"Int J Cardiol"},{"key":"2979_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamacardio.2018.2559","volume":"3","author":"AS Tahhan","year":"2018","unstructured":"Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld JA, O\u2019Connor CM, Butler J (2018) Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. JAMA Cardiol 3:1011\u20131019. https:\/\/doi.org\/10.1001\/jamacardio.2018.2559","journal-title":"JAMA Cardiol"},{"key":"2979_CR16","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.jacc.2018.02.070","volume":"71","author":"PE Scott","year":"2018","unstructured":"Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY, Geller RJ, Elahi M, Temple RJ, Woodcock J (2018) Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol 71:1960\u20131969. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.070","journal-title":"J Am Coll Cardiol"},{"key":"2979_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1161\/circoutcomes.110.868307","volume":"3","author":"C Melloni","year":"2010","unstructured":"Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, Dolor RJ, Douglas PS, Mark DB, Newby LK (2010) Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 3:135\u2013142. https:\/\/doi.org\/10.1161\/circoutcomes.110.868307","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02979-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02979-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02979-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T19:13:40Z","timestamp":1629486820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02979-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2979"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02979-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21984\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"assertion":[{"value":"6 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was provided by the Regional Ethical Review Board in Ume\u00e5, Sweden (registration number 2015\/419-31).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}